Top Posts
Crescent Biopharma (Nasdaq: CBIO) Closes Public Offering Raising...
Delcath Systems Inc. (Nasdaq: DCTH) Grants Equity Awards...
Stoke Therapeutics (Nasdaq: STOK) Grants Stock Options to...
Marvel Biosciences Corp. (TSXV: MRVL) Plans Non-Brokered Private...
Annexon (Nasdaq:ANNX) Grants Inducement Awards to Two New...
Protagonist Therapeutics (Nasdaq:PTGX) Grants Inducement Awards to New...

feature stories

Noveris Health Sciences Inc. (CSE:NVRS) Joins Life Sciences British Columbia to Enhance Ecosystem Engagement
NeuroThera Labs Inc. (TSXV: NTLX) Initiates Phase IIb Clinical Trial Site for Tourette Syndrome Treatment in Germany
Ocumetics Technology Corp. Advances Vision Restoration Technology with Positive Clinical Results and Financing Initiative
BetterLife Pharma Inc. (CSE: BETR) Appoints John W. LaRocca to Board of Directors
DiagnosTear Technologies Inc. (CSE:DTR) Announces Positive Interim Analytical Results for TeaRx™ Red Eye Clinical Study
Ocumetics Technology Corp. Proposes Private Placement to Raise Up To $2 Million for Clinical Trials and R&D

Breaking News

BreakingPartner / M&A
Aqemia and Sanofi Expand Drug Discovery Collaboration with New Therapeutic Target Nomination
BreakingR&D - Therapy
Kalaris Therapeutics (Nasdaq:KLRS) Announces Positive Additional Data from Phase 1a Trial of TH103
BreakingEventsR&D - Therapy
Veradermics (NYSE: MANE) Presents Subgroup Data from Phase 2/3 Study of VDPHL01 in Male Pattern Hair Loss at AAD Innovation Academy
BreakingRegulatory
Red Light Holland Corp. (CSE: TRIP) to Rebrand as Rhelion Life Sciences Corp. as it Focuses on Psychedelic Drug Discovery
BreakingR&D - Therapy
ThalassaX Therapeutics Doses First Patient in U.S. Phase I Clinical Trial of Novel Oncology Drug Candidate CS231295
BreakingPartner / M&A
Vector Science & Therapeutics (TSXV:PAIN) and Caresyntax Announce Real-World Evidence Partnership for VectorMist
BreakingPartner / M&A
Arch Biopartners (TSX Venture:ARCH) Advances Chronic Kidney Disease Program with Bioengineering Lab Engagement
BreakingR&D - Therapy
Clearmind Medicine (Nasdaq:CMND) Highlights Supportive Regulatory Developments for Novel Neuropsychiatric and Addiction Disorder Treatments
BreakingNew Product
FDA Approves LIPFENDRA® (enlicitide) Tablets, the First Oral PCSK9 Inhibitor for Lowering LDL-C (NYSE:MRK)
BreakingR&D - Therapy
Moderna (NASDAQ:MRNA) Doses First U.S. Participant in Phase 1 Study of mRNA-4200 Cancer Therapy
BreakingR&D - Therapy
Greenwich LifeSciences (Nasdaq:GLSI) Updates Phase III FLAMINGO-01 Trial to Combine All Patient Groups in Europe and U.S.
BreakingR&D - Therapy
Medicus Pharma Ltd. (NASDAQ: MDCX) Receives FDA Feedback and IRB Approval for Optimized Teverelix Phase 2 Study

More Breaking News…

Biotech2

DAYFILE:

Market News

×

Welcome!

BiotechReporter.news is a Leads & Copy Publication

Leads & Copy is a Media “news tip” source, providing Industry Reporters story Leads, written as Publishable CP-style Copy.

By Subscribing you will receive Daily Biotech Story Leads via email 10:30 am Mon-Fri.